Drug intelligence / Profile preview

BG2205

Development stage
Phase 1
Lead developer
Guangzhou Bio-gene Technology
Modality
CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
Administration
Intravenous
01

Overview

BG2205 is an autologous bispecific Chimeric Antigen Receptor (CAR)-T cell therapy developed by Guangzhou Bio-gene Technology. It is designed to target both CD19 and B-cell maturation antigen (BCMA) simultaneously. The drug's mechanism of action involves immunologic cytotoxicity and T lymphocyte replacements, leading to the effective elimination of naive B cells, mature B cells, and plasma cells. This profound depletion of the B-lymphocyte population is intended to induce immune reconstitution and restore normal immune function, making it a potential treatment for autoimmune diseases and certain hematologic malignancies.

Other names
CD19-BCMA CAR-T Cell TherapyCD-19-BCMA CAR-T Cell TherapyCD 19-BCMA CAR-T Cell Therapy
02

Targets

BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on BG2205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG2205.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call